The 12.5mg dose is not one of the standard FDA-approved dose levels (which jump from 10mg to 15mg), but it is commonly used in compounded protocols as an intermediate step
Survodutide, the agent they are seeking to bring forward, exemplifies this approach
The treatment is still undergoing Phase 3 clinical trials conducted by Eli Lilly, and it has not yet been submitted for regulatory approval to the Medicines and Healthcare products Regulatory Agency (MHRA)
Based on these results it appears justified to test, in human subjects, the hypothesis that dietary inulin-type fructans could play a role in the management of obesity and diabetes through their capacity to promote secretion of endogenous gastrointestinal peptides involved in appetite regulation.
The price for both strengths is the same
And theyre also wanting to ultimately discontinue the medication. Some patients dont like side effects such as nausea and constipation